{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:33:51Z","timestamp":1793885631790,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.lungcan.2013.11.011","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T12:56:44Z","timestamp":1385038604000},"page":"265-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2274-1702","authenticated-orcid":false,"given":"P.A.","family":"Zucali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Perrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lorenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.L.","family":"Ceresoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"De Vincenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Simonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gianoncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"De Sanctis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9587-7870","authenticated-orcid":false,"given":"L.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-9492","authenticated-orcid":false,"given":"A.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2013.11.011_bib0005","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1586\/era.09.2","article-title":"Future developments in the management of malignant pleural mesothelioma","volume":"9","author":"Zucali","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0010","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0015","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2003.06.122","article-title":"Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma","volume":"21","author":"Scagliotti","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0020","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0025","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdm501","article-title":"Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)","volume":"19","author":"Castagneto","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0030","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carbolatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0035","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/annonc\/mdi187","article-title":"Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","volume":"16","author":"Manegold","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0040","first-page":"2626","article-title":"Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma?","volume":"17","author":"Vogelzang","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0045","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0959-8049(02)80018-1","article-title":"Phase II trial of ZD0473 as second-line therapy in mesothelioma","volume":"38","author":"Giaccone","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0050","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1200\/JCO.2003.05.123","article-title":"Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study","volume":"21","author":"Fizazi","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0055","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.lungcan.2004.11.015","article-title":"Raltitrexed\u2013oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients","volume":"48","author":"Porta","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0060","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/01243894-200607000-00002","article-title":"Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program","volume":"1","author":"Janne","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0065","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/JTO.0b013e31802f3813","article-title":"Pemetrexed as second-line treatment in malignant pleural mesothelioma (MPM) after platinum-based first-line treatment","volume":"2","author":"Sorensen","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/cncr.22366","article-title":"Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma","volume":"109","author":"Fennell","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0075","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0080","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.23337","article-title":"Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"112","author":"Zucali","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0085","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2009.27.3649","article-title":"Phase II Study of asparagine-glycine-arginine-human tumor necrosis factor {alpha}, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma","volume":"28","author":"Gregorc","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ctrv.2009.09.003","article-title":"Second-line treatment for malignant pleural mesothelioma","volume":"36","author":"Ceresoli","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0100","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/1756-0500-5-482","article-title":"Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience","volume":"5","author":"Bearz","year":"2012","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0105","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1200\/JCO.2007.12.5641","article-title":"Phase II study of vinflunine in malignant pleural mesothelioma","volume":"5","author":"Talbot","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0110","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.2000.18.23.3912","article-title":"Phase II study of vinorelbine in patients with malignant pleural mesothelioma","volume":"18","author":"Steele","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0115","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"Muers","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0120","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jjco\/hyi127","article-title":"Triplet chemotherapy with cisplatin, gemcitabin and vinorelbina for malignant pleural mesothelioma","volume":"35","author":"Maruyama","year":"2005","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0125","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.lungcan.2004.08.005","article-title":"Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma","volume":"47","author":"Fennell","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0130","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.bjc.6604421","article-title":"Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma","volume":"99","author":"Sorensen","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0135","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbina in relepsed malignant pleural mesothelioma","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0140","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0145","unstructured":"National Cancer Institute: Common Toxicity Criteria Manual, version 3.0, August 9, 2006. http:\/\/ctep.cancer.gov\/reporting\/ctc.html."},{"key":"10.1016\/j.lungcan.2013.11.011_bib0150","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation of incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0155","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0160","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/1078-0432.982.11.3","article-title":"Pemetrexed in malignant pleural mesothelioma","volume":"11","author":"Hazarika","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0165","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1118\/1.1688211","article-title":"Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques","volume":"31","author":"Armato","year":"2004","journal-title":"Med Phys"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0170","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0959-8049(01)00398-7","article-title":"Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas","volume":"38","author":"Van Glabbeke","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lungcan.2013.11.011_bib0175","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European organization for research and treatment of cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J Clin Oncol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500213005229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500213005229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T08:03:07Z","timestamp":1688803387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500213005229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0169500213005229"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2013.11.011","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2013.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}